Back to Search
Start Over
Current state and next-generation CAR-T cells in multiple myeloma.
- Source :
- Blood Reviews; Jul2022, Vol. 54, pN.PAG-N.PAG, 1p
- Publication Year :
- 2022
-
Abstract
- Chimeric antigen receptor T cells (CAR-T cells) have emerged as a potentially transformative new approach to treating hematological malignancies. Ide-cel, an autologous B cell maturation antigen (BCMA) targeting CAR-T cells, has recently been approved to treat multiple myeloma (MM). Here, we review the main clinical trials of CAR-T cells in MM with the most advanced autologous BCMA-directed ide-cel and cilta-cel, the human CARs orva-cel and CT053, the alternative manufacturing process with P-BCMA-101 and bb21217, the dual CAR GC012F and the allogenic BCMA-directed CAR-T cells ALLO-715. In light of those clinical data, we provide an overview of CAR-T cells' main potential resistance mechanisms, including antigen loss, antigen spreading, anti-CAR antibodies, CAR-T cell exhaustion, and the emergence of a non-permissive microenvironment. Finally, we describe the principal area of research to build the next generation of CAR-T cells, with armored-, gated- or commuting-CARs, CARs associated with knock out of specific genes, and CAR-T cells made from γδT cells or NK cells. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 0268960X
- Volume :
- 54
- Database :
- Supplemental Index
- Journal :
- Blood Reviews
- Publication Type :
- Academic Journal
- Accession number :
- 157003008
- Full Text :
- https://doi.org/10.1016/j.blre.2022.100929